Golgi Neurosciences announces Breye Therapeutics to start Phase 1b/2a clinical trials
Golgi Neurosciences announces Breye Therapeutics to start Phase 1b/2a clinical trials Milan (Italy) – Golgi Neurosciences Srl is thrilled to share an update from its portfolio company Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology. Breye Therapeutics has initiated phase 1b/2a clinical trial, with the scope … Read more